Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2 SARSCoV2 Coronavirus Disease COVID Nasal Neutralizing antibodies Intranasal vaccine eBioMedicine SSI_dk karolinskainst koebenhavns_uni
Study: Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy. Image Credit: Sergey Chips / Shutterstock
About the study In the present study, researchers assessed the anti-SARS-CoV-2 efficacy of an s.c. prime-i.n. vaccination regimen in Syrian hamsters. The nasal and lung samples were obtained for histopathological examination and evaluation of SARS-CoV-2 titers by quantitative reverse transcription-polymerase chain reaction analysis for the SARS-CoV-2 envelope gene.
The vaccination regimen provided immune protection against SARS-CoV-2 infection in the lower airways and pulmonary pathologies; however, SARS-CoV-2 could not be totally eliminated from the upper airways. Despite this, the s.c./i.n. vaccination regimen effectively prevented onward transmission of SARS-CoV-2 in a magnitude significantly greater than that observed among onward unvaccinated control animals.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancyIn an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).
Read more »
BNT162b2 SARS-CoV-2 vaccinations found to reduce incidence of long COVID symptomsResearchers assessed the association between Pfizer-BioNTech’s SARS-CoV-2 BNT162b2 messenger ribonucleic acid (mRNA) vaccination and the incidence of post-COVID-19 symptoms among Israeli adults.
Read more »
SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical useIn a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).
Read more »
Small molecule inhibitor found to be effective against SARS-CoV-2 variantsIn a new study, researchers developed RK-33, a small molecule inhibitor of DDX3, and evaluated its efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs).
Read more »
What is the risk of SARS-CoV-2 infection among gout patients?What is the risk of SARS-CoV-2 infection among gout patients? SARSCoV2 COVID19 Coronavirus Gout GoutPatients
Read more »
Transplacental passage of specific IgG in maternal SARS-CoV-2 infectionTransplacental passage of specific IgG in maternal SARS-CoV-2 infection infection pregnancy COVID19 coronavirus covid SARSCoV2 antibody maternal disease
Read more »